天眼查商业履历信息显示，西藏易明西雅医药科技股份有限公司，成立于2007年，位于拉萨市，是一家 以从事批发业为主的企业。企业注册资本19067.775万人民币，实缴资本7491.4792万人民币。公司法定 代表人为许可。 通过天眼查大数据分析，西藏易明西雅医药科技股份有限公司共对外投资了6家企业，参与招投标项目 10次，知识产权方面有商标信息11条，专利信息16条，此外企业还拥有行政许可15个。 来源：金融界 金融界消息 截至2025年8月14日收盘，易明医药（002826）报收于23.5元，上涨5.33%，换手率 17.45%，成交量30.41万手，成交金额7.16亿元。 资金流向方面，今日主力资金净流入1.08亿元，占比成交额15.13%。其中，超大单净流入6231.90万 元、占成交额8.7%，大单净流入4605.43万元、占成交额6.43%，中单净流出流出1005.56万元、占成交 额1.4%，小单净流出9831.78万元、占成交额13.73%。 易明医药最新一期业绩显示，截至2025一季报，公司营业总收入1.49亿元、同比减少7.41%，归属净利 润1879.39万元，同比减少32.64%，扣非净利 ...

| 5,730,750 | 其中：无限售条件股份 | | 1.09% | 5,730,750 | 1.09% | | --- | --- | --- | --- | --- | --- | | （有限合伙） | | | | | | | 0 | 有限售条件股份 | | 0% | 0 | 0% | | 4,342,500 | 合计持有股份 | | 0.83% | 4,342,500 | 0.83% | | 天津皓晖资产管理合伙企业 | | | | | | | 4,342,500 | 其中：无限售条件股份 | | 0.83% | 4,342,500 | 0.83% | | （有限合伙） | | | | | | | 0 | 有限售条件股份 | | 0% | 0 | 0% | | 4,304,250 | 合计持有股份 | | 0.82% | 4,304,250 | 0.82% | | 天津晖众资产管理合伙企业 | | | | | | | 4,304,250 | 其中：无限售条件股份 | | 0.82% | 4,304,250 | 0.82% | | （有限合伙） | | | | | | | 0 | 有限售条件股份 | ...

截至2025年8月13日15时，塞力医疗最新股价为31.09元，较前一交易日收盘价上涨1.91元。当日开盘价 为29.04元，最高触及31.31元，最低下探28.59元，成交量为55.62万手，成交金额达16.71亿元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 塞力医疗属于医药商业板块，公司主营业务为医疗商业和工业业务。2024年财务数据显示，其商业业务 收入占比达97.09%，工业业务收入占比2.91%。 来源:金融界 8月12日晚间，公司发布公告称实际控制人温伟已办理完成300万股股份的解除质押手续。本次解除质押 后，温伟累计质押股份数降至530万股，占其持股比例的55.01%。公司控股股东及实际控制人合计质押 股份数为1930万股，占公司总股本的10.1%。 8月13日主力资金净流入1.09亿元，占流通市值的1.84%。近五个交易日主力资金累计净流入1.44亿元， 占流通市值的2.42%。 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

北海康成-B(01228)再涨超12%，截至发稿，涨11.98%，报1.87港元，成交额1844.94万港元。 同时，公司两家附属与百洋医药股份附属百洋附属订立一份战略合作及独家商业服务协议。据此，相关 附属同意委任百洋附属为独家合同销售组织，于内地、香港及澳门推广集团的若干产品。 消息面上，北海康成公布，向百洋医药（301015）(301015.SZ)发行7497万股新股，每股作价1.34港元， 较停牌前收报折让19.76%，认购事项所得款项净额约9866.18万港元，拟用于商业化产品的研发；营销 及推广活动；偿还贷款融资；及日常营运。完成后，百洋医药将持有公司股本14.99%，后者已表示其 无意于三年内收购公司任何控股股份。 ...

Core Viewpoint - The company, Huaren Health, has shown a positive trend in its stock performance and financial metrics, indicating potential growth opportunities in the pharmaceutical sector [1][2]. Financing and Trading Data - On August 12, Huaren Health's stock increased by 0.72%, with a trading volume of 294 million yuan. The financing buy-in amounted to 31.94 million yuan, while the financing repayment was 31.34 million yuan, resulting in a net financing buy of 599,900 yuan [1]. - As of August 12, the total financing and securities balance for Huaren Health was 141 million yuan, representing 6.13% of its market capitalization. This financing balance is above the 90th percentile of the past year, indicating a high level of activity [1]. - In terms of securities lending, on August 12, Huaren Health had no shares sold short, with a total of 0 shares in the lending balance, which is below the 30th percentile of the past year, indicating low short-selling activity [1]. Company Overview - Huaren Health, established on June 29, 2001, is located in Hefei, Anhui Province. The company was listed on March 1, 2023, and primarily engages in pharmaceutical agency, retail, and terminal procurement [1]. - The revenue composition of Huaren Health includes: 80.25% from Western and Chinese medicines, 4.62% from health products, 4.23% from other goods, 4.00% from medical devices, 3.28% from traditional Chinese medicine pieces, 1.89% from specialty raw materials, and 1.72% from other supplementary products [1]. Financial Performance - For the period from January to March 2025, Huaren Health reported a revenue of 1.267 billion yuan, reflecting a year-on-year growth of 14.71%. The net profit attributable to shareholders was 61.22 million yuan, marking a 28.15% increase compared to the previous year [2]. - As of March 31, 2025, the number of shareholders for Huaren Health was 18,000, an increase of 9.39% from the previous period, while the average number of circulating shares per person decreased by 8.58% to 8,309 shares [2]. Dividend and Shareholding - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3]. - As of March 31, 2025, Hong Kong Central Clearing Limited was no longer among the top ten circulating shareholders of Huaren Health [3].

Financial Performance - The company reported a net profit of -7.61 million yuan for the first half of 2025, a decrease of 162.95% year-on-year [1] - Total revenue for the same period was 2.157 billion yuan, down 3.06% compared to the previous year [1] - The gross profit margin increased by 29.78% to 10.82%, while the net profit margin fell to -0.42%, a decrease of 193.59% [1] Key Financial Metrics - The company's operating expenses, including sales, management, and financial costs, totaled 203 million yuan, accounting for 9.42% of revenue, an increase of 41.11% year-on-year [1] - Earnings per share dropped to -0.08 yuan, a decline of 161.54% compared to the previous year [1] - The company's cash flow from operating activities was -0.08 yuan per share, a decrease of 315.44% year-on-year [1] Changes in Financial Items - Accounts receivable increased by 89.58% due to uncollected sales [3] - Long-term equity investments rose by 81.63% as the company increased its investments in associated companies [3] - Construction in progress surged by 280.19% due to new non-pharmaceutical production line projects [3] Cash Flow Analysis - The net cash flow from operating activities improved significantly, with a net increase of 1.86 billion yuan from the previous year [6] - Cash and cash equivalents decreased by 113.56% due to bank loan repayments [5] - The company’s cash flow from financing activities was -143.23%, primarily due to loan repayments [5] Business Model and Strategy - The company relies heavily on research and marketing to drive performance, necessitating a thorough examination of these underlying drivers [5] - The return on invested capital (ROIC) was reported at 1.74%, indicating weak capital returns compared to the historical median of 9.58% [5]

证券代码：600833 证券简称：第一医药 公告编号：2025-037 上海第一医药股份有限公司 2024年年度权益分派实施公告 ● 每股分配比例 A股每股现金红利0.22元 本次利润分配方案经公司2025年6月20日的2024年年度股东大会审议通过。 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本223,086,347股为基数，每股派发现金红利0.22元（含税），共 计派发现金红利49,078,996.34元。 1.实施办法 无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上海证券交易所收 市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易的投资者可于红 利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分公司保 管，待办理指定交易后再进行派发。 2.自行发放对象 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实 ...

证券代码：600833 证券简称：第一医药 公告编号：2025-037 上海第一医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.22元 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 本次利润分配以方案实施前的公司总股本223,086,347股为基数，每股派发现金红利0.22 元（含税） ，共计派发现金红利49,078,996.34元。 三、 相关日期 | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/18 | － | 2025/8/19 | 2025/8/19 | | 四、 分配实施办法 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 20 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责 ...

Core Viewpoint - Beihai Kangcheng-B (01228) has announced a strategic partnership with a subsidiary of Qingdao Baiyang Pharmaceutical Co., Ltd. (301015.SZ) to promote certain products in mainland China, Hong Kong, and Macau through an exclusive commercial service agreement [1] Group 1 - The agreement establishes Baiyang's subsidiary as the exclusive Contract Sales Organization (CSO) for promoting the group's products in the specified regions [1] - The promotion is subject to the upstream authorization agreements established by the group's member companies and the respective product authorization [1] - Baiyang's affiliated companies may act as distributors for the products in the relevant regions at Baiyang's discretion [1]